2013
DOI: 10.4236/abb.2013.48a2009
|View full text |Cite
|
Sign up to set email alerts
|

Biological agents in the treatment of uveitis

Abstract: Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biological process and therefore defined as "biologics" has been successfully used in the treatment of immunemediated rheumatic diseases. These drugs target different pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
5
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 68 publications
0
5
0
Order By: Relevance
“…Golimumab, Intliximab, Adalimumab, Ustekinumab, Secukinumab were studied in noninfection uveitis. Etanercept, although paradoxically responsible in very rare cases of the onset of uveitis in patients with inflammatory rheumatic conditions, is still an effective drug for the treatment of inflammatory ocular diseases [93][94][95][96][97][98][99][100][101][102][103][104][105][106][107].…”
Section: Review and Discussionmentioning
confidence: 99%
“…Golimumab, Intliximab, Adalimumab, Ustekinumab, Secukinumab were studied in noninfection uveitis. Etanercept, although paradoxically responsible in very rare cases of the onset of uveitis in patients with inflammatory rheumatic conditions, is still an effective drug for the treatment of inflammatory ocular diseases [93][94][95][96][97][98][99][100][101][102][103][104][105][106][107].…”
Section: Review and Discussionmentioning
confidence: 99%
“…Golimumab, Intliximab, Adalimumab, Ustekinumab, Secukinumab were studied in noninfection uveitis. Etanercept, although paradoxically responsible in very rare cases of the onset of uveitis in patients with inflammatory rheumatic conditions, is still an effective drug for the treatment of inflammatory ocular diseases [93][94][95][96][97][98][99][100][101][102][103][104][105][106][107].…”
Section: Review and Discussionmentioning
confidence: 99%
“…Golimumab, Intliximab, Adalimumab, Ustekinumab, Secukinumab were studied in noninfection uveitis. Etanercept, although paradoxically responsible in very rare cases of the onset of uveitis in patients with inflammatory rheumatic conditions, is still an effective drug for the treatment of inflammatory ocular diseases [93][94][95][96][97][98][99][100][101][102][103][104][105][106][107].…”
Section: Review and Discussionmentioning
confidence: 99%